

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177 and Stock code: 40150)

SHARE PURCHASE PLAN

This announcement is made by Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rules 13.09 and 37.47B(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company resolved to approve a share purchase plan (the “**Share Purchase Plan**”) on 31 March 2022 pursuant to which the Company will, subject to market conditions, (1) buy back ordinary shares of the Company (the “**Shares**”) from the open market (the “**Share Buy-back**”), and (2) under the restricted share award scheme adopted by the Company on 5 January 2018 (the “**Share Award Scheme**”), instruct the trustee responsible for administering the Share Award Scheme to purchase Shares from the open market (the “**Incentive Share Purchase**”), for an aggregate consideration of not exceeding HK\$1 billion (the “**Share Purchase Amount**”) over the following 1 year. The Board will review from time to time and determine at its sole discretion how the Share Purchase Amount will be allocated between the Share Buyback and the Incentive Share Purchase.

The Share Buy-back is intended to enhance the return to the shareholders of the Company (“**Shareholders**”). The Shares bought back will be cancelled. Any Share Buy-back contemplated by the Company will be conducted pursuant to the general mandates granted to the Directors by the Shareholders at annual general meetings from time to time authorizing them to buy back Shares and in compliance with the Listing Rules, the Codes on Takeovers and Mergers and Share Buy-backs, and all other applicable laws and regulations.

Incentive Share Purchase provides the necessary share reserve for the Share Award Scheme. The incentive shares are used to encourage and retain selected participants in the scheme to work for the Group and to reward selected participants for achieving performance targets, thereby motivating them to maximise the value of the Company. Details of the Share Award Scheme are set out in the Company's announcement dated 5 January 2018.

The Board is of the view that the implementation of the Share Purchase Plan is in the best interests of the Company and the Shareholders as a whole.

Securities holders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 31 March 2022

As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.